|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Together, these results indicate a substantial involvement of neutrophil-derived MPO in the pathology of 5XFAD model of AD and suggest MPO as a potential therapeutic target in AD.
|
31611761 |
2019 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Polymorphisms in the promoter region of <i>MPO</i> distinctly contribute to AD risk possibly through regulating MPO concentration.
|
29296208 |
2017 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We studied the cellular localization of MPO and compared numbers of MPO cells in various brain regions between neurologically healthy individuals and patients with Parkinson's disease (PD) or Alzheimer's disease (AD; n = 10-25).
|
28466093 |
2017 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We suggest that aberrant huMPO expression in astrocytes leads to a specific pattern of phospholipid peroxidation and neuronal dysfunction contributing to AD.
|
19059911 |
2009 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Additionally, a functional biallelic (G/A) polymorphism in the promoter region (-463) of the MPO gene has been associated with a gender-specific risk factor for AD, but reports of this association have been inconsistent.
|
16484808 |
2006 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Rarely found in normal brain tissue, myeloperoxidase has been detected in microglia associated with Alzheimer's disease plaques.
|
16641309 |
2006 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The increase in neuronal myeloperoxidase expression we observed in Alzheimer disease brains raises the possibility that the enzyme contributes to the oxidative stress implicated in the pathogenesis of the neurodegenerative disorder.
|
15255951 |
2004 |
|
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
LHGDN |
Neuronal expression of myeloperoxidase is increased in Alzheimer's disease.
|
15255951 |
2004 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A functional myeloperoxidase (MPO) promoter polymorphism, -463GA, has been associated with incidence or severity of inflammatory diseases, including atherosclerosis and Alzheimer's disease, and some cancers.
|
14668325 |
2004 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms.
|
15023809 |
2004 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of MPO-G/G and A2M-Val/Val genotypes synergistically increased the risk of AD (OR, 25.5; 95% CI, 4.65-139.75).
|
15023809 |
2004 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism in the myeloperoxidase gene (MPO) has previously been associated with AD susceptibility.
|
12946561 |
2003 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study in the Spanish population as well as the meta-analysis argue against the hypothesis that the MPO gene is causally related to AD.
|
12052532 |
2002 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Association between Alzheimer's disease and a functional polymorphism in the Myeloperoxidase gene.
|
11161635 |
2001 |
|
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the MPO polymorphism is a gender-specific risk factor for Alzheimer's disease.
|
9918702 |
1999 |
|
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|